
## Monika Wagner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6058438/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Moving Towards Accountability for Reasonableness – A Systematic Exploration of the Features of Legitimate Healthcare Coverage Decision-Making Processes Using Rare Diseases and Regenerative Therapies as a Case Study. International Journal of Health Policy and Management, 2019, 8, 424-443.	0.9	10
2	Development of a Framework Based on Reflective MCDA to Support Patient–Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States. Advances in Therapy, 2018, 35, 81-99.	2.9	14
3	Applying Reflective Multicriteria Decision Analysis (MCDA) to Patient–Clinician Shared Decision-Making on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the Spanish Context. Advances in Therapy, 2018, 35, 1215-1231.	2.9	7
4	Authors' Reply to Gandjour: "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation― Pharmacoeconomics, 2017, 35, 605-606.	3.3	0
5	EXPLORING VALUES OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES USING REFLECTIVE MULTICRITERIA AND RARE DISEASE CASE. International Journal of Technology Assessment in Health Care, 2017, 33, 504-520.	0.5	14
6	Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA. BMC Cancer, 2017, 17, 272.	2.6	34
7	Identifying Value(s): A Reflection on the Ethical Aspects of MCDA in Healthcare Decisionmaking. , 2017, , 29-46.		9
8	Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation. Pharmacoeconomics, 2016, 34, 285-301.	3.3	53
9	Pragmatic Multicriteria Decision Analysis (MCDA) Combined With Advanced Pharmacoepidemiology for Benefit-Risk Assessments of Medicines Adapted to the Real-Life Constraints of Regulators: Development and Case Study. Therapeutic Innovation and Regulatory Science, 2016, 50, 620-631.	1.6	8
10	WHICH CRITERIA ARE CONSIDERED IN HEALTHCARE DECISIONS? INSIGHTS FROM AN INTERNATIONAL SURVEY OF POLICY AND CLINICAL DECISION MAKERS. International Journal of Technology Assessment in Health Care, 2013, 29, 456-465.	0.5	80
11	Bridging Health Technology Assessment (HTA) and Efficient Health Care Decision Making with Multicriteria Decision Analysis (MCDA). Medical Decision Making, 2012, 32, 376-388.	2.4	131
12	Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa. Cost Effectiveness and Resource Allocation, 2012, 10, 2.	1.5	36
13	From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmaking. Cost Effectiveness and Resource Allocation, 2012, 10, 9.	1.5	163
14	Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada. BMC Health Services Research, 2011, 11, 329.	2.2	92
15	Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decisionmaking framework to growth hormone for Turner syndrome patients. Cost Effectiveness and Resource Allocation, 2010, 8, 4.	1.5	84
16	Evidence and Value: Impact on DEcisionMaking – the EVIDEM framework and potential applications. BMC Health Services Research, 2008, 8, 270.	2.2	179